- Details
- Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible populati...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
- Details
- Diane Newman dialogues with Jeff Albaugh to discuss Albaugh's 30-year experience, his freely accessible guide for men with erectile dysfunction, and the significant role patient narratives and research play in making informed choices. Focusing on prostate cancer treatments, they delve into the effects on erectile function and recovery timeline. They explore different treatments, emphasizing the va...
|
- Details
- In a conversation between Alicia Morgans and Atish Choudhury, they discuss a study called A-DREAM that is examining the right balance of treatment duration for patients with metastatic prostate cancer. They note that androgen deprivation therapy (ADT) works well for many patients, but it can also lead to complications such as weight gain, muscle loss, and cardiovascular issues over time. To combat...
|
- Details
- In a conversation with Alicia Morgans, Stephen Freedland discusses a study he presented that analyzes Veterans Affairs’ data on men who had received either surgery or radiation therapy for prostate cancer and later developed a biochemical recurrence. The focus is on the 'doubling time' of PSA, a significant prognostic factor. According to the study, the majority of patients with a doubling time of...
|
- Details
- Zach Klaassen interviews Alicia Morgans about an edition focusing on prostate cancer survivorship in European Urology Focus. Morgans stresses the importance of survivorship and explains the diverse experiences of prostate cancer survivors, ranging from patients with low-grade cancer to those with incurable prostate cancer. The edition aims to address issues significant to these various populations...
|
- Details
- In a conversation between Alicia Morgans and David Olmos, they discussed the exciting findings from Olmos' presentation focusing on prostate cancer patients with BRCA mutations. Dr. Olmos highlighted that BRCA1 and BRCA2 mutation patients, regardless of germline or somatic origin, generally have worse outcomes compared to other patients. The CAPTURE study he spearheaded, which involved multiple co...
|
- Details
- Phillip Koo talks with Jeremie Calais about the EMBARK trial and the impact of PSMA PET on patient population characterization. The discussion explores how the EMBARK trial began back in 2015 before the existence of PSMA PET and how its introduction has affected the understanding and definition of patient populations in prostate cancer studies. Calais explains how their team retrospectively looked...
|
- Details
- Derek Kang joins Alicia Morgans to discuss an ongoing exercise study focused on Black patients with prostate cancer undergoing Androgen Deprivation Therapy. This groundbreaking project is designed to study the potential effects of regular exercise on these patients' physical function, metabolic health, and prostate cancer outcomes. The study hopes to mitigate the higher risk of cardiovascular dise...
|
- Details
- Jeremie Calais discusses a retrospective analysis of the use of PSMA PET in salvage radiotherapy with Alicia Morgans. The study focused on the application of PSMA PET findings to the treatment of patients with biochemical recurrence after radical prostatectomy, with approximately 4-5 years of follow-up. They discovered that disease presence correlates with negative outcomes and that the number of...
|
